David H. Chu

1.3k total citations
26 papers, 982 citations indexed

About

David H. Chu is a scholar working on Dermatology, Immunology and Molecular Biology. According to data from OpenAlex, David H. Chu has authored 26 papers receiving a total of 982 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Dermatology, 7 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in David H. Chu's work include Dermatology and Skin Diseases (6 papers), T-cell and B-cell Immunology (5 papers) and Nail Diseases and Treatments (4 papers). David H. Chu is often cited by papers focused on Dermatology and Skin Diseases (6 papers), T-cell and B-cell Immunology (5 papers) and Nail Diseases and Treatments (4 papers). David H. Chu collaborates with scholars based in United States, Canada and Hong Kong. David H. Chu's co-authors include Arthur Weiss, Craig T. Morita, Mark J. Levis, Philip Wedegaertner, Henry R. Bourne, Paul T. Wilson, Nicolai S. C. van Oers, R. Rowley, Jean‐François Peyron and Hergen Spits and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and The EMBO Journal.

In The Last Decade

David H. Chu

24 papers receiving 958 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David H. Chu United States	10	501	379	148	141	110	26	982
L. M. Gardner United States	13	497 1.0×	305 0.8×	138 0.9×	34 0.2×	117 1.1×	13	1.0k
Kelly M. Loyet United States	19	656 1.3×	536 1.4×	166 1.1×	296 2.1×	322 2.9×	33	1.4k
Gregory G. Burrows United States	27	369 0.7×	1.3k 3.4×	240 1.6×	176 1.2×	26 0.2×	62	1.9k
Ivo J. Huijbers Netherlands	24	954 1.9×	315 0.8×	595 4.0×	47 0.3×	162 1.5×	43	1.6k
Peter van Tuinen United States	16	473 0.9×	212 0.6×	144 1.0×	27 0.2×	47 0.4×	32	1.0k
Valerie Stewart United States	12	745 1.5×	583 1.5×	342 2.3×	95 0.7×	36 0.3×	21	1.3k
K Toyoshima Japan	11	510 1.0×	329 0.9×	282 1.9×	188 1.3×	53 0.5×	13	1.0k
Catherina L. Salanga United States	16	588 1.2×	490 1.3×	561 3.8×	128 0.9×	236 2.1×	19	1.2k
Yu Kawakami Japan	13	320 0.6×	347 0.9×	69 0.5×	47 0.3×	95 0.9×	28	865
Greg Coffey United States	17	395 0.8×	385 1.0×	220 1.5×	143 1.0×	28 0.3×	44	1.0k

Countries citing papers authored by David H. Chu

Since Specialization

Citations

This map shows the geographic impact of David H. Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Chu more than expected).

Fields of papers citing papers by David H. Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Chu. The network helps show where David H. Chu may publish in the future.

Co-authorship network of co-authors of David H. Chu

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Chu. A scholar is included among the top collaborators of David H. Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Chu. David H. Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Simpson, Eric L., Lawrence F. Eichenfield, Kim Papp, et al.. (2025). Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis. 37(1). 75–83. 1 indexed citations

Eichenfield, Lawrence F., Vimal H. Prajapati, Joseph Browning, et al.. (2025). Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial. Pediatric Dermatology. 42(2). 296–304. 3 indexed citations

Simpson, Eric L., Mark Boguniewicz, Lawrence F. Eichenfield, et al.. (2024). 53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis. Journal of the American Academy of Dermatology. 91(3). AB281–AB281.

Heath, Candrice, et al.. (2024). Patient and Healthcare Provider Perspectives on Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey. Dermatology and Therapy. 14(11). 3083–3095. 3 indexed citations

Chovatiya, Raj, et al.. (2024). Patient and Healthcare Provider Perspectives on the Pathway to Diagnosis of Seborrheic Dermatitis in the United States. Advances in Therapy. 41(12). 4433–4445.

Eichenfield, Lawrence F., Mark Boguniewicz, Eric L. Simpson, et al.. (2024). 505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials. British Journal of Dermatology. 190(Supplement_2). ii10–ii11. 1 indexed citations

Eichenfield, Lawrence F., Mark Boguniewicz, Eric L. Simpson, et al.. (2023). ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED Results: FROM INTEGUMENT-1/2 PHASE 3 TRIALS. Annals of Allergy Asthma & Immunology. 131(5). S91–S91. 4 indexed citations

Sun, Jing, Xun Ma, David H. Chu, et al.. (2019). Biomaterials and Advanced Biofabrication Techniques in hiPSCs Based Neuromyopathic Disease Modeling. Frontiers in Bioengineering and Biotechnology. 7. 373–373. 6 indexed citations

Chu, David H., Chung Hang Jonathan Choi, Siu‐Kai Kong, et al.. (2018). A comprehensive web tool for toehold switch design. Bioinformatics. 34(16). 2862–2864. 28 indexed citations

10.

Greenstein, Vivienne C., et al.. (2009). Normal Versus High Tension Glaucoma. Journal of Glaucoma. 19(3). 151–157. 62 indexed citations

11.

Chu, David H. & Seth J. Orlow. (2006). The Physician-Scientist. Journal of Investigative Dermatology. 126(3). 527–527. 6 indexed citations

12.

Greenstein, Vivienne C., et al.. (2006). Detecting Early Functional Damage in Glaucoma Suspect and Ocular Hypertensive Patients With the Multifocal VEP Technique. Journal of Glaucoma. 15(4). 321–327. 13 indexed citations

13.

Chu, David H., et al.. (2004). Patterns of Visual Field Abnormalities in Normal versus High Tension Glaucoma. Investigative Ophthalmology & Visual Science. 45(13). 2133–2133. 1 indexed citations

14.

Chu, David H., et al.. (2004). Verrucous plaque on the foot. Journal of Cutaneous Pathology. 31(3). 271–273. 5 indexed citations

15.

Chu, David H., Elizabeth K. Hale, & Perry Robins. (2003). Generalized eruptive keratoacanthomas. Dermatology Online Journal. 9(4). 36–36. 9 indexed citations

16.

Hunter, Sharon, et al.. (1999). Structural requirements of Syk kinase for Fcγ receptor– phagocytosis. Experimental Hematology. 27(5). 875–884. 11 indexed citations

17.

Chu, David H., Nicolai S. C. van Oers, Marie Malissen, et al.. (1999). Pre-T Cell Receptor Signals Are Responsible for the Down-Regulation of Syk Protein Tyrosine Kinase Expression. The Journal of Immunology. 163(5). 2610–2620. 51 indexed citations

18.

Chu, David H., Craig T. Morita, & Arthur Weiss. (1998). The Syk family of protein tyrosine kinases in T‐cell activation and development. Immunological Reviews. 165(1). 167–180. 210 indexed citations

19.

Kadlecek, Theresa A., Nicolai S. C. van Oers, Leo Lefrançois, et al.. (1998). Differential Requirements for ZAP-70 in TCR Signaling and T Cell Development. The Journal of Immunology. 161(9). 4688–4694. 109 indexed citations

20.

Chu, David H., Hergen Spits, Jean‐François Peyron, et al.. (1996). The Syk protein tyrosine kinase can function independently of CD45 or Lck in T cell antigen receptor signaling.. The EMBO Journal. 15(22). 6251–6261. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact